Reelin deficiency or dysfunction and methods related thereto

A dysfunctional, vitilin technology, applied in the direction of anhydride/acid/halide active ingredients, etc., can solve problems such as the inherent causes of neuropathy problems that cannot be alleviated

Inactive Publication Date: 2007-03-21
MARTEK BIOSCIENCES CORP (N D GES D STAATES DELAWARE) COLUMBIA
View PDF11 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, neuropsychiatric or neurodegenerative drugs continue to be developed to relieve symptoms but still fail to alleviate the underlying cause of the neurological problem

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0140] Quantification of Fibrillin Levels in Infant Patient Samples to Determine the Nature of Neurological Dysfunction and Receive Treatment

[0141] The following example demonstrates how the diagnosis of autism and thus DHA treatment can be determined by testing the concentration of fibrillin in a patient sample.

[0142] patient sample

[0143] Patient blood samples were obtained by venipuncture or drawn from infants aged 1 to 18 months. Samples were collected in tubes containing anticoagulants (EDTA or heparin) and spun to separate the plasma from the cell pellet. The resulting plasma was frozen at -80°C until needed.

[0144] control sample

[0145] Blood samples are drawn from appropriate, disease-negative control subjects in the same manner as test subjects. Similarly, the resulting plasma was frozen at -80°C until needed.

[0146] Quantification of Fibrillin Levels Using Quantitative Western Blot

[0147] Five microliters of each patient's plasma was diluted int...

Embodiment 2

[0154] Quantitative determination of fibrillin levels in patients for the diagnosis of schizophrenia

[0155] The following example demonstrates how the diagnosis of schizophrenia and thus the course of treatment with DHA can be facilitated by the quantitative measurement of fibrillin levels in peripheral blood samples.

[0156] patient sample

[0157] Blood samples are drawn by venipuncture of the patient and the samples are collected in tubes containing anticoagulants (EDTA or heparin). Samples were centrifuged to remove plasma from whole cells and the resulting plasma was frozen at -80°C until needed.

[0158] control sample

[0159] Blood samples are drawn from appropriate, disease-negative control subjects in the same manner as test subjects. The resulting plasma was similarly frozen at -80°C until needed.

[0160] Quantification of Fibrillin Levels by Fluorescence Microplate Immunoassay

[0161] Fifty microliters of each patient's plasma was diluted two-fold in an e...

Embodiment 3

[0166] Example 3: Quantification of Fibrillin levels in patients for the diagnosis of bipolar disorders.

[0167] The following example demonstrates how the diagnosis of bipolar disorder and thus the course of treatment with DHA can be facilitated by the quantitative measurement of trellin levels in peripheral blood samples.

[0168] patient sample

[0169] Blood samples are drawn by venipuncture of the patient and the samples are collected in tubes containing anticoagulants (EDTA or heparin). Samples were centrifuged to remove plasma from whole cells and the resulting plasma was frozen at -80°C until needed.

[0170] control sample

[0171] Blood samples are drawn from appropriate, disease-negative control subjects in the same manner as test subjects. The resulting plasma was similarly frozen at -80°C until needed.

[0172] Quantification of Fibrillin Levels Using a Porous Fluorescent Protein Microchip Immunoassay

[0173]25 microliters of each patient's plasma was dilut...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A method of measuring Reelin as a biomarker, to non-destructively assess or predict DHA levels in the brain and in other, currently inaccessible or difficult-to-access, key components of the central nervous system (CNS) is described. Also described is a method to prevent, delay the onset of, or treat Reelin deficiency or dysfunction and / or a disease or condition associated with Reelin deficiency or dysfunction, comprising administering to a patient diagnosed with or suspected of having a Reelin deficiency or dysfunction an amount of a PUFA, and particularly an omega-3 PUFA, and more particularly, docosahexaenoic acid (DHA) or a precursor or source thereof, to compensate for the effects of Reelin deficiency or dysfunction in the patient. Also described is a method to prevent or reduce development defects or disorders associated with Reelin dysfunction or deficiency through the supplemental use of polyunsaturated fatty acids (PUFAs- unsaturated fatty acids having two or more double bonds), and particularly highly unsaturated fatty acids (HUFAs- unsaturated fatty acids having three or more double bonds), and more particularly a HUFA selected from arachidonic acid (ARA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA), and even more particularly omega-3 HUFAs, and more particularly DHA, to: compensate for reduced fatty acid binding protein or function thereof in the patient; compensate for reduced brain lipid binding protein or function thereof in the patient; improve the activity of fatty acid binding proteins in the patient.

Description

field of invention [0001] The present invention relates generally to a method of treating Reelin deficiency or dysfunction and diseases or conditions associated therewith by supplementing the use of drugs with high affinity for brain lipid-binding proteins (BLBPs), and especially omega- 3 and / or omega-6 polyunsaturated fatty acids (PUFAs), such as docosahexaenoic acid (DHA 22:6n-3). The present invention also relates to the use of quillin as a biomarker of DHA and other PUFA levels in the brain and other tissues. Background of the invention [0002] Neurological or neuropsychiatric conditions and diseases continue to present challenges in prediction, differentiation and diagnosis. Some of the more important neurodegenerative disorders (eg, schizophrenia, bipolar disorder, dyslexia, movement disorders, attention deficit hyperactivity disorder (ADHD), epilepsy, autism, Parkinson's disease, dementia, Alzheimer's disease, Peroxisome proliferator-activated disease (PPAR), multi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/20
Inventor 约翰·P·莫斯曼马克·W·莫斯洛里·A·埃利斯
Owner MARTEK BIOSCIENCES CORP (N D GES D STAATES DELAWARE) COLUMBIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap